Different Glucose Metabolic Features According to Cancer and Immune Cells in the Tumor Microenvironment

• Published in: Frontiers in oncology Vol. 11; p. 769393
• Main Authors: Choi, Hongyoon, Na, Kwon Joong
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 13-12-2021
• Subjects: glucose metabolism; glucose transporter; immunotherapy; Oncology; single cell RNA sequencing; tumor microenvironment; tumor microenvironment; glucose transporter; single cell RNA sequencing; glucose metabolism; immunotherapy
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.769393

A close metabolic interaction between cancer and immune cells in the tumor microenvironment (TME) plays a pivotal role in cancer immunity. Herein, we have comprehensively investigated the glucose metabolic features of the TME at the single-cell level to discover feasible metabolic targets for the tumor immune status.
We examined expression levels of glucose transporters (GLUTs) in various cancer types using The Cancer Genome Atlas (TCGA) data and single-cell RNA-seq (scRNA-seq) datasets of human cancer tissues including melanoma, head and neck, and breast cancer. In addition, scRNA-seq data of immune cells in the TME acquired from human melanoma after immune checkpoint inhibitors were analyzed to investigate the dynamics of glucose metabolic profiles of specific immune cells.
Pan-cancer bulk RNA-seq showed that the GLUT3-to-GLUT1 ratio was positively associated with immune cell enrichment score. The scRNA-seq datasets of various human cancer tissues showed that GLUT1 was highly expressed in cancer cells, while GLUT3 was highly expressed in immune cells in TME. The scRNA-seq data obtained from human melanoma tissues pre- and post-immunotherapy showed that glucose metabolism features of myeloid cells, particularly including GLUTs expression, markedly differed according to treatment response.
Differently expressed GLUTs in TME suggest that GLUT could be a good candidate a surrogate of tumor immune metabolic profiles and a target for adjunctive treatments for immunotherapy.